An­tios' HBV col­lab axed af­ter clin­i­cal hold, but biotech be­lieves safe­ty in­ci­dent is not treat­ment-re­lat­ed

The FDA has placed a clin­i­cal hold on a Phase IIa study of An­tios Ther­a­peu­tics’ in­ves­ti­ga­tion­al he­pati­tis B med, CEO Greg Mayes con­firmed to End­points News in an emailed state­ment.

A safe­ty re­port was de­liv­ered to the biotech on May 17 af­ter a pa­tient dosed in a triple com­bi­na­tion co­hort of the study had ex­pe­ri­enced brady­car­dia and hy­poten­sion. The triple com­bo in­clud­ed An­tios’ ATI-2173, As­sem­bly Bio­sciences’ ve­bi­corvir and Viread, an ap­proved an­tivi­ral for HIV and he­pati­tis B.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER